TEVA PHARMACEUTICAL INDUSTRIES LTD

Teva Pharmaceutical Industries Ltd. announced that Moody's Ratings has upgraded its corporate credit rating to Baa3 from Ba1, achieving investment-grade status with a stable outlook. Moody's cited Teva's successful growth strategy, including innovative products, an expanded pipeline, and continued debt reduction supported by earnings growth. Teva's CFO, Eli Kalif, highlighted this as a major milestone in the company's transformation and a validation of its "Pivot to Growth" strategy, enhancing financial flexibility and access to a broader investor base. This upgrade follows a similar action by Fitch Ratings in May 2026.

Teva Pharmaceutical Industries Ltd. completed the acquisition of Emalex Biosciences for approximately $700 million in June 2026, significantly impacting its second-quarter financial results. The company reported a net loss attributable to Teva of $576 million for Q2 2026, a decrease from a net income of $282 million in the prior year, largely due to $724 million in acquired in-process R&D expenses related to the acquisition. Net revenues for the quarter were $4,142 million, a slight decline year-over-year.

Teva Pharmaceutical Industries Ltd. reported Q2 2026 revenues of $4.1 billion, a 1% decrease year-over-year, primarily due to lower generics sales. However, its key innovative brands collectively grew 43% in local currency to over $1 billion, leading the company to raise its 2026 outlook for these brands to approximately $3.7 billion. The quarter saw a GAAP loss per share of $0.49, largely due to the $700 million acquisition of Emalex Biosciences and its asset ecopipam, while non-GAAP diluted EPS was $0.02. Teva also announced the replacement of its ADS program with a direct NYSE listing of ordinary shares.

Teva Pharmaceutical Industries Ltd. announced the availability of its Q2 2026 Aide Memoire on its investor website. This document compiles previously released public information to help investors prepare for the second quarter 2026 results. The company expects to release its Q2 2026 results on Wednesday, July 29, 2026, at 7:00 a.m. ET, followed by a conference call at 8:00 a.m. ET on the same day.

Teva Pharmaceutical Industries Ltd. announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ecopipam. This investigational therapy is a potential first-in-class treatment for pediatric Tourette syndrome and has received FDA Orphan Drug and Fast Track designations. The NDA is supported by positive Phase 3 data, recently published in JAMA Neurology, which demonstrated that ecopipam significantly delayed time to relapse compared with placebo and was generally well-tolerated. This submission represents a significant milestone for Teva's innovative pipeline and its "Pivot to Growth" strategy.

Teva Pharmaceutical Industries Ltd. announced the schedule for its second-quarter 2026 financial results. The company will issue a press release on Wednesday, July 29, 2026, at 7:00 a.m. ET, followed by a conference call and live webcast at 8:00 a.m. ET. Interested parties need to register in advance for phone participation, and the webcast will be accessible via Teva's investor relations website, with a replay available within 24 hours.

Teva Pharmaceutical Industries Ltd. announced the closing of its acquisition of Emalex Biosciences, strengthening its late-stage pipeline with ecopipam, an investigational asset for pediatric Tourette syndrome. The acquisition involved an upfront payment of $700 million, with potential for up to an additional $200 million in commercial milestone payments and net sales-based royalties. Ecopipam, a selective dopamine D1 receptor antagonist, has received FDA Orphan Drug and Fast Track designations, and a U.S. NDA submission is anticipated in the second half of 2026. This move aligns with Teva's "Pivot to Growth" strategy, expanding its neuroscience pipeline to address a significant unmet medical need.

Teva Pharmaceuticals announced new data from three studies highlighting the comprehensive symptom improvement from AUSTEDO® and AUSTEDO XR® in tardive dyskinesia (TD) patients. The IMPACT-TD Registry showed reductions in Abnormal Involuntary Movement Scale (AIMS) scores in all participants, associated with improved daily living activities, including for those with mild TD. The 3-year RIM-TD study reinforced the importance of sustained treatment, with over 50% of patients responding by week 15 and additional patients improving with continued therapy. Furthermore, a caregiver education study demonstrated an effective strategy to improve TD diagnosis rates.

Teva Pharmaceuticals announced new real-world survey data for AUSTEDO and AUSTEDO XR, demonstrating significant improvements in quality of life for patients with Huntington's disease (HD) chorea and their caregivers. The study revealed that 60-71% of patients reported improved quality of life due to better movement control, and 74% saw improvements in chorea movements. Caregivers also experienced reduced impact on their daily lives, with 77% reporting improvements in social life and emotional wellbeing.

Teva Pharmaceutical Industries Ltd. announced that its President and CEO, Richard Francis, will participate in a fireside chat at the Goldman Sachs Global Healthcare Conference. The event is scheduled for Monday, June 8, 2026, at 8:00 A.M. Eastern Time. Investors can access live and archived webcasts of the presentation through Teva's Investor Relations website.